Clinical trial
Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients…
NCT00276276 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00276276 |
|---|---|
| Title | Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer |
| Official title | An Open-Label, Multicentre, Randomised, Phase III Comparator Study of Active Symptom Control Alone or in Combination With Oral Topotecan in Patients With Relapsed Resistant SCLC |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lung Cancer, Small Cell |
| Intervention type | Drug |
| Interventions | topotecan |
| Enrollment | 141 |
| Start date | Nov 1, 2000 |
| First posted | Jan 13, 2006 |
| Last update posted | Apr 15, 2013 |
| Countries | Bulgaria, Hungary, Netherlands, Russia, Ukraine, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: